AllSci News
AstraZeneca's Imfinzi plus Padcev improves survival in muscle-invasive bladder cancer
AstraZeneca (LSE/STO/NYSE: AZN) has reported positive VOLGA trial results in bladder cancer, with perioperative durvalumab (Imfinzi) combined with...
GT Biopharma's B7-H3-targeted NK cell engager enters Phase I testing across solid tumors
GT Biopharma (Nasdaq: GTBP), based in San Francisco, has dosed the first patient in a Phase I basket trial evaluating GTB-5550, a B7-H3-targeted natural...
Degron Therapeutics closes USD 40 million Series A extension for molecular glue degraders
A targeted protein degradation company with a clinical-stage molecular glue degrader program has secured additional capital to fund its lead oncology asset...
AstraZeneca enters three-year license agreement with Owkin for K Pro agentic AI platform
AstraZeneca (LSE/NYSE: AZN) has entered a three-year license agreement with Owkin, a privately held AI company founded in 2016 and headquartered across New...
UroGen's mitomycin shows durable response in Phase III ENVISION bladder cancer trial
Three-year durability data from the ZUSDURI ENVISION trial reinforce the clinical profile of mitomycin (Zusduri) as a non-surgical option for recurrent...
Silexion's RNAi therapy shows increased MHC-I surface expression in preclinical models of KRAS-mutated pancreatic cancer
Silexion Therapeutics (Nasdaq: SLXN), a Cayman Islands-based clinical-stage biotechnology company, has reported preclinical data showing that its lead siRNA...
Regenxbio's hits Phase III endpoints with gene therapy for Duchenne muscular dystrophy
Regenxbio (Nasdaq: RGNX), the Rockville, Maryland-based gene therapy company, reported positive topline data from the pivotal Phase III portion of its...
Mezzion Pharma secures financing to advance udenafil Phase III trial in Fontan circulation
Mezzion Pharmaceuticals has announced the completion of an institutional financing round to support continued execution of the FUEL-2 trial, its global...
Cantex and Headlamp Health partner on azeliragon for multiple sclerosis depression and fatigue
Cantex Pharmaceuticals (Weston, Fla.) and Headlamp Health (San Francisco) announced a collaboration to apply Headlamp’s Lumos AI platform to the clinical development…
Biogen to contine with tau-targeted diranersen despite missed endpoint in early Alzheimer's Phase II
Biogen (Nasdaq: BIIB) reported topline Phase II results for diranersen (BIIB080) in early Alzheimer's disease on May 14, marking the first randomized Phase...
FDA approves BeOne Medicines’ Beqalzi for relapsed or refractory mantle cell lymphoma
A new BCL-2 inhibitor will be made available in the relapsed mantle cell lymphoma (MCL) space after the US FDA granted accelerated…
FDA gives the nod for Taiho’s Inqovi with venetoclax in newly diagnosed acute myeloid leukemia
An oral alternative to intravenous hypomethylating therapy will be made available for acute myeloid leukemia (AML) patients after the US FDA’s approval…
METiS TechBio raises USD 269m via Hong Kong listing, attracting USD 148m cornerstone commitments
I need to flag a conflict between the system instructions and the user prompt before producing the article.
Novo Nordisk's oral semaglutide achieves 21.6% weight loss in early responders in Phase III obesity trial
New sub-analyses from the phase III OASIS 4 trial show that oral semaglutide 25 mg (Wegovy pill) produced 21.6% weight loss in early responders by week 64,...
Aurigene secures non-exclusive CRISPR/Cas9 license from ERS Genomics for drug discovery
Aurigene Pharmaceutical Services, a contract research and manufacturing subsidiary of Dr. Reddy's Laboratories (NYSE: RDY), has secured a non-exclusive...
The AllSci Brief
Free, systematic R&D and deal news. Daily.